• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
COVID-19 Management

Prospective Trial Results (France): Hydroxychloroquine and Azithromycin Provide No Clinical Benefit for COVID-19

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • A small French study by Gautret et al. (International Journal of Antimicrobial Agents, 2020) found 100% viral clearance in COVID-19 patients who received hydroxychloroquine and azithromycin
  • Molina et al. (Médecine et Maladies Infectieuses, 2020) followed up this study by assessing virologic and clinical outcomes using the same dosing regimen

METHODS:

  • Prospective study
  • Participants
    • Consecutive hospitalized COVID-19 patients
  • Intervention
    • Hydroxychloroquine, 600 mg/d for 10 days
    • Azithromycin 500 mg Day 1, 250 mg days 2 to 5

RESULTS:

  • 11 patients were treated
    • 7 men | mean (range) age 58.7 years (20 to 77)
    • 8 had significant comorbidities (obesity, solid and hematological cancer, HIV-infection)
  • At time of treatment 10 of the 11 patients had a fever and received nasal oxygen therapy
  • Within 5 days
    • 1 patient had died
    • 2 had been transferred to the ICU
  • In one patient, hydroxychloroquine and azithromycin were discontinued after 4 days due to a prolongation of QT interval
  • Viral clearance at days 5 to 6 after treatment: 80%
    • At days 5 to 6 after treatment, nasopharyngeal swabs were still positive for viral RNA in 80% of patients (95% CI, 49 to 94%)

CONCLUSION:

  • This study found no evidence for a clinical benefit of combination hydroxychloroquine and azithromycin in COVID-19 patients
    • Results corroborates the results of a study from China, which also found that this combination did not affect viral clearance or clinical outcome
    • The authors state

Ongoing randomised clinical trials with hydroxychloroquine should provide a definitive answer regarding the alleged efficacy of this combination and will assess its safety

Learn More – Primary Sources:

No Evidence of Rapid Antiviral Clearance or Clinical Benefit with the Combination of Hydroxychloroquine and Azithromycin in Patients with Severe COVID-19 Infection (Médecine et Maladies Infectieuse, 2020)

Hydroxychloroquine and Azithromycin as a Treatment of COVID-19: Results of an Open-Label Non-Randomized Clinical Trial (International Journal of Antimicrobial Agents, 2020)

Get COVID-19 Research Summaries Direct to Your Phone, with ObGFirst

Try it Free »

image_pdfFavoriteLoadingFavorite
< Previous
All COVID-19 Management Posts
Next >

Related ObG Topics:

Use of Convalescent Plasma in Critically Ill COVID-19 Patients: Results from a Preliminary Study
Surgical Masks Reduce Viral Shedding
MMWR Reports on Initial US COVID-19 Experience: Demographics, Mortality and Outcomes 

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Download Your ObG App
HERE!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site